compared to its average ratio and a 36-month beta value of 0.70. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The average price point forecasted by analysts for Anavex Life Sciences Corp. (AVXL) is $47.75, which is $40.65 above the current market price. The public float for AVXL is 79.37M, and currently, short sellers hold a 21.27% ratio of that float. The average trading volume of AVXL on September 19, 2023 was 832.58K shares.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
AVXL) stock’s latest price update
The stock of Anavex Life Sciences Corp. (NASDAQ: AVXL) has decreased by -0.42 when compared to last closing price of 7.13. Despite this, the company has experienced a -8.39% fall in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-08-02 that NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2023, taking place on August 7-8, 2023.
AVXL’s Market Performance
Anavex Life Sciences Corp. (AVXL) has seen a -8.39% fall in stock performance for the week, with a -12.99% decline in the past month and a -15.58% plunge in the past quarter. The volatility ratio for the week is 7.10%, and the volatility levels for the past 30 days are at 4.21% for AVXL. The simple moving average for the past 20 days is -9.46% for AVXL’s stock, with a -20.33% simple moving average for the past 200 days.
Analysts’ Opinion of AVXL
Many brokerage firms have already submitted their reports for AVXL stocks, with Cantor Fitzgerald repeating the rating for AVXL by listing it as a “Neutral.” The predicted price for AVXL in the upcoming period, according to Cantor Fitzgerald is $11 based on the research report published on December 06, 2022 of the previous year 2022.
AVXL Trading at -12.90% from the 50-Day Moving Average
After a stumble in the market that brought AVXL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.41% of loss for the given period.
Volatility was left at 4.21%, however, over the last 30 days, the volatility rate increased by 7.10%, as shares sank -13.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.19% lower at present.
During the last 5 trading sessions, AVXL fell by -8.58%, which changed the moving average for the period of 200-days by -19.67% in comparison to the 20-day moving average, which settled at $7.79. In addition, Anavex Life Sciences Corp. saw -23.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVXL starting from MISSLING CHRISTOPHER U, who sale 268,000 shares at the price of $7.98 back on Jun 28. After this action, MISSLING CHRISTOPHER U now owns 1,018,210 shares of Anavex Life Sciences Corp., valued at $2,139,310 using the latest closing price.
Stock Fundamentals for AVXL
The total capital return value is set at -34.77, while invested capital returns managed to touch -32.71. Equity return is now at value -36.30, with -33.40 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 14.95.
Conclusion
To put it simply, Anavex Life Sciences Corp. (AVXL) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
